CHI Insight Pharma Reports

CHA Advances Reports are a service of Cambridge Healthtech Advisors. Advances Reports are written by experts who collaborate with CHA to provide a series of reports that evaluate the salient trends in pharmaceutical technology, business, and therapy markets.

Advances Reports offer:
  • Current information and analysis of R&D technologies, therapeutic markets, and critical business issues.
  • Analysis of the probability of success for various applications of each technology.
  • Interviews with key personnel in companies at the forefront of technological advances.
  • Competitive insight on the business strategies and activities of key companies.
CHI Insight Pharma Reports
 

List of reports from CHI Insight Pharma Reports

< prev 1    3  
Vaccines: The End of Illness Overview
4/10/2014 | published by: CHI Insight Pharma Reports
... efficient healthcare. Their low cost, extended protection and the impossibility of their circumvention through development of resistance on the part of the target pathogen have been longstanding attributes of vaccines. Today, vaccine technology is undergoing ...  |  read more...
$2,495.00
Ocular Disorders: Rising Therapeutics, Technologies, and Devices
12/1/2013 | published by: CHI Insight Pharma Reports
... including wet and dry age-related macular degeneration (AMD) while alsoproviding alternative therapeutic options for various ocular complications. In an interview with several companies including Oraya Therapeutics, VisionCare Ophthalmic Technologies, Omeros, and Kala Pharmaceuticals, representatives mentioned ...  |  read more...
$1,995.00
Prenatal Diagnostics: Invasive testing, noninvasive testing, and rising maternal screening methods for preeclampsia and preterm labor
12/1/2013 | published by: CHI Insight Pharma Reports
... preeclampsia and preterm labor. This report discusses improvements in invasive procedures (karyotyping vs. cytogenetics), and the rise of noninvasive screening methods and their impact on prenatal healthcare. Although covering standard invasive procedure, this report focuses ...  |  read more...
$2,495.00
Epigenetics: Emerging Targets, Available Technologies, Expert Interviews, and an Epigenetic Community Perspective - Overview
12/1/2013 | published by: CHI Insight Pharma Reports
... mostly pertaining to epigenetic targets, and the reasons they are being investigated. Several companies have kindly disclosed several strategies, methods, and techniques that they use for either target identification or technology development. Report Features Include: ...  |  read more...
$2,495.00
Macrocycles: Discovery, Development & Technologies - Overview
12/1/2013 | published by: CHI Insight Pharma Reports
... what macrocycles are and the pharmacokinetic properties they exhibit Reviews specifics in technologies and current research in development Detailed descriptions of company overviews, technology platforms, benefits, challenges, competitive advantages, partnerships and future aspirations Macrocycles are ...  |  read more...
$2,495.00
Digital PCR Technology Report: An Insight to Vendors, Costs & the End User Community
5/1/2013 | published by: CHI Insight Pharma Reports
... is a new application in research and development allowing for higher sensitivity and specificity than real-time PCR. This allows researchers to closely examine rare genetic mutations (including single nucleotide polymorphisms), copy number variations, viruses, prenatal ...  |  read more...
$2,495.00
Advances in Clinical Genome Sequencing and Diagnostics: Implementing Advances in Next-Gen Sequencing to Clinical Diagnostics and the Challenges of Genome Interpretation
3/1/2013 | published by: CHI Insight Pharma Reports
... and business models. Aspects discussed and presented include: Progress in clinical genome sequencing. Organizations leading the way in generating clinical data and its interpretation. Determining the causality of documented variants in genetic disease. Clinical genome ...  |  read more...
$2,495.00
Therapies for Solid Tumors: Pipelines, Markets, and Business Considerations
9/1/2012 | published by: CHI Insight Pharma Reports
... of emerging drugs—for treatment of solid tumors, discussing: The various types of solid tumors that are the focus of the most pharmacological effort, including information about the specific disease, its incidence and epidemiology, current treatment ...  |  read more...
$2,495.00
The New Generation of Antibody Therapeutics: Current Status and Future Prospects - Overview
6/1/2012 | published by: CHI Insight Pharma Reports
... strategies. Following a review of the business environment and market forces, this report examines: The state of the art, and the needs and direction, of antibody technology today Antibody conjugates and other payloads: construction, clinical ...  |  read more...
$2,495.00
R&D Trends Melanoma - Drug resistance provides an opportunity for drug developers
5/15/2012 | published by: CHI Insight Pharma Reports
... in Phase II trials. Early-stage developers are focusing on new targets in the MAPK pathway and immunomodulator targets such as PD-1 in an attempt to limit acquired resistance. Features and benefits In-depth analysis of melanoma ...  |  read more...
$3,800.00
Treatment Algorithms: Rectal Cancer – Inclusion of chemoradiation can influence treatment and prescribing trends
4/26/2012 | published by: CHI Insight Pharma Reports
... off patent over the forecast period and the approval of new therapies, treatment of this growing market is set to evolve. Features and benefits Disease overview assessing, etiology, risk factors, screening procedures, and patient segmentation ...  |  read more...
$7,600.00
Treatment Algorithms: Colon Cancer – Treatment dictated by stage, prior therapy, and reimbursement
4/26/2012 | published by: CHI Insight Pharma Reports
... come off patent over the forecast period and the approval of new therapies, treatment of this growing market is set to evolve. Features and benefits Disease overview assessing, etiology, risk factors, screening procedures, and patient ...  |  read more...
$7,600.00
R&D Trends: Non-Small Cell Lung Cancer - Mutation analyses continue driving treatment choices
4/10/2012 | published by: CHI Insight Pharma Reports
... and tumor specific antigens. Features and benefits Analysis of the non-small cell lung cancer pipeline – development stage, therapeutic class, molecular targets, and changes in the last two years. In-depth analysis of current comparator therapy ...  |  read more...
$3,800.00
Epidemiology: Malignant Melanoma
4/5/2012 | published by: CHI Insight Pharma Reports
... growth and will be strongest in the US and the five major EU markets. Malignant melanoma is rare in Japan and will increase more slowly over the forecast period. Features and benefits Gain insight into ...  |  read more...
$5,700.00
Backup Compound Strategies: Commercial and Tactical Considerations - Overview
4/1/2012 | published by: CHI Insight Pharma Reports
... significant investments. Planning optimal backup compound strategies is often difficult. This Insight Pharma Report: Describes how companies are addressing strategic and tactical issues concerning backup compounds and predicts how they are likely to do so ...  |  read more...
$9,950.00
Fragment-Based Drug Discovery: Technologies, Applications, and Pipelines - Overview
4/1/2012 | published by: CHI Insight Pharma Reports
... Drug Discovery: Technologies, Applications, and Pipelines, examines the many issues that must be considered vis-à-vis employment of fragment-based screening approaches. Chemical considerations are examined, including the impact of high-throughput screening (HTS) and its attendant shortcomings, ...  |  read more...
$795.00
Epidemiology: Ovarian Cancer – Stable or declining in younger women and increasing among older women
3/2/2012 | published by: CHI Insight Pharma Reports
... is driven by the increase in incident cases among the growing elderly population, as trends among younger age groups will be flat or in very gradual decline. Features and benefits Gain insight into market potential ...  |  read more...
$3,800.00
Hematological Cancer Therapies
3/1/2012 | published by: CHI Insight Pharma Reports
... well as challenges and opportunities for pharmaceutical companies. This report discusses: The different types of hematological cancers, including information about the specific disease, its epidemiology, subtypes and/or staging if appropriate, current therapies, and patient prognosis. ...  |  read more...
$2,495.00
Pharma Blogging: Speaking Out
3/1/2012 | published by: CHI Insight Pharma Reports
... manner than traditional media channels have allowed. Pharma blogs also provide companies with the means of expressing their own opinions on stories that concern them, as well as presenting the possibility of entering into a ...  |  read more...
$495.00
Hematological Cancer Therapies: Pipelines, Markets, and Business Considerations - Overview
2/1/2012 | published by: CHI Insight Pharma Reports
... well as challenges and opportunities for pharmaceutical companies. This report discusses: The different types of hematological cancers, including information about the specific disease, its epidemiology, subtypes and/or staging if appropriate, current therapies, and patient prognosis. ...  |  read more...
$2,495.00
Oncology Partnering Terms & Agreements - Overview
2/1/2012 | published by: CHI Insight Pharma Reports
... includes: Trends in oncology dealmaking in the biopharma industry since 2007 Analysis of oncology deal structure Access to headline, upfront, milestone and royalty data Case studies of real-life oncology deals Access to over 2,700 oncology ...  |  read more...
$2,686.00
Cancer Vaccines Market Study
1/1/2012 | published by: CHI Insight Pharma Reports
... cancer vaccines, which was designed to focus on standardized immunogenic vaccines vs. autologous cell therapies or passive immunotherapies. Included in this 20 page Industry Market Study is Expert Interviews, Market Data, Analysis and Survey Results.  |  read more...
$495.00
High-Content Analysis: Technologies, Applications, and Market Dynamics
12/1/2011 | published by: CHI Insight Pharma Reports
... of “industrialized drug discovery.” This report discusses: Development of the HCA field from the commercial, scientific, and technological perspectives Technologies that underlie HCA and the full range of systems that are available today Applications of ...  |  read more...
$1,795.00
The PI3K/Akt/mTOR Pathway
11/1/2011 | published by: CHI Insight Pharma Reports
... This report includes: Pipeline reviews of PI3K, Akt, mTOR, and dual kinase inhibitors in development and an assessment of the current prospects for each approach Role of the PI3K/Akt/mTOR cascade in various diseases and potential ...  |  read more...
$2,495.00
New Trends in Preventive and Therapeutic Vaccines
10/1/2011 | published by: CHI Insight Pharma Reports
... viruses, and HIV Therapeutic vaccines that target HIV, HCV, asthma and allergy, type 1 diabetes, multiple sclerosis, psoriasis, arthritis, atherosclerosis, transplant rejection, Alzheimer’s disease, periodontitis, substance abuse, obesity, cachexia, and age-related macular degeneration Therapeutic cancer ...  |  read more...
$2,495.00
< prev 1    3  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!